Compound ID | 313
BP-102
Class: Beta-lactam
| Agent Type: | Semisynthetic; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Cell wall synthesis inhibitor |
| Target Pathogen: | Active against methicillin-resistant and -susceptible Staphylococcus aureus |
| Combined with other compounds: | The addition of tazobactam improved Gram negative activity |
| Description: | A carbacephem |
| Institute where first reported: | Blanca Pharmaceuticals; NAEJA Pharmaceutical; SRI International; Ulysses Pharmaceuticals |
| Year first mentioned: | 2005 |
| Development status: | Experimental |
| External links: | |
| Citation: | https://link.springer.com/article/10.2165/00003495-200666080-00005 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.